Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06436183 · ClinicalTrials.gov registry record · Phase 2
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Apollo Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT06436183: Completed Phase 2 study, sponsored by Apollo Therapeutics.
NCT06436183 is a Phase 2 study that has completed, run by Apollo Therapeutics. The registered enrollment target is 62 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06436183, a Phase 2 study, has completed, sponsored by Apollo Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.
Primary Outcome
An EASI score is a tool used to measure the extent (area) and severity of atopic eczema. The EASI utilizes area assessments that rate the four involved regions on a 0% to 100% scale for each region. The scores are added up for each of the four body regions (head, arms, trunk, and legs). For each of these components, the individual scores are added together to calculate the EASI score, which ranges from 0 to 72. The higher the EASI score, the more severe the AD.
Interventions
- DRUG Placebo
- DRUG Camoteskimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2025-08-12 |
| Phase | Phase 2 |
What the finished NCT06436183 record still lists
NCT06436183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06436183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06436183 about?
NCT06436183 is a clinical study titled "A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis". This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.
What is the current status of trial NCT06436183?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2024-05-01. Estimated completion is 2025-08-12.
What interventions are being tested in trial NCT06436183?
The interventions under investigation include: Placebo (DRUG), Camoteskimab (DRUG).
Who is sponsoring clinical trial NCT06436183?
This trial is sponsored by Apollo Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06436183's enrollment target sits among peer trials
62 1016th of 2000 higher than 975 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI